Al-Mankhee A, Moatasim Y, El Taweel A, Gomaa M, Rabiee O, Gado M
Pathogens. 2025; 13(12.
PMID: 39770311
PMC: 11728743.
DOI: 10.3390/pathogens13121051.
Huang J, Ma Q, Su Z, Cheng X
Int J Mol Sci. 2024; 25(19).
PMID: 39409149
PMC: 11477007.
DOI: 10.3390/ijms251910820.
Han T, Song L, Niu X, Qiu M, Wang Y, Wang J
Heliyon. 2024; 10(9):e30489.
PMID: 38726116
PMC: 11079089.
DOI: 10.1016/j.heliyon.2024.e30489.
Chan J, Yuan S, Chu H, Sridhar S, Yuen K
Nat Rev Microbiol. 2024; 22(7):391-407.
PMID: 38622352
DOI: 10.1038/s41579-024-01036-y.
Jiang J, Pei H, Li J, Li M, Zou Q, Lv Z
Brief Bioinform. 2024; 25(2).
PMID: 38366802
PMC: 10939380.
DOI: 10.1093/bib/bbae037.
Development of SARS-CoV-2 entry antivirals.
Dong M, Galvan Achi J, Du R, Rong L, Cui Q
Cell Insight. 2024; 3(1):100144.
PMID: 38323318
PMC: 10844678.
DOI: 10.1016/j.cellin.2023.100144.
HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor intranasal administration.
Lu Y, Shen F, He W, Li A, Li M, Feng X
Acta Pharm Sin B. 2023; .
PMID: 37360013
PMC: 10219671.
DOI: 10.1016/j.apsb.2023.05.030.
Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines.
Guo L, Lin S, Chen Z, Cao Y, He B, Lu G
Signal Transduct Target Ther. 2023; 8(1):197.
PMID: 37164987
PMC: 10170451.
DOI: 10.1038/s41392-023-01472-x.
DRAVP: A Comprehensive Database of Antiviral Peptides and Proteins.
Liu Y, Zhu Y, Sun X, Ma T, Lao X, Zheng H
Viruses. 2023; 15(4).
PMID: 37112801
PMC: 10141206.
DOI: 10.3390/v15040820.
SARS-CoV-2 Spike-Mediated Entry and Its Regulation by Host Innate Immunity.
Yu S, Hu H, Ai Q, Bai R, Ma K, Zhou M
Viruses. 2023; 15(3).
PMID: 36992348
PMC: 10059852.
DOI: 10.3390/v15030639.
SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors.
Xia S, Wang L, Jiao F, Yu X, Xu W, Huang Z
Emerg Microbes Infect. 2023; 12(1):2178241.
PMID: 36748716
PMC: 9970205.
DOI: 10.1080/22221751.2023.2178241.
Exploring Highly Conserved Regions of SARS-CoV-2 Spike S2 Subunit as Targets for Fusion Inhibition Using Chimeric Proteins.
Polo-Megias D, Cano-Munoz M, Berruezo A, Laumond G, Moog C, Conejero-Lara F
Int J Mol Sci. 2022; 23(24).
PMID: 36555153
PMC: 9778920.
DOI: 10.3390/ijms232415511.
A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein.
Pang W, Lu Y, Zhao Y, Shen F, Fan C, Wang Q
Cell Res. 2022; 32(12):1068-1085.
PMID: 36357786
PMC: 9648449.
DOI: 10.1038/s41422-022-00746-3.
Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
Zhu Y, Hu Y, Liu N, Chong H, He Y
Antiviral Res. 2022; 208:105445.
PMID: 36265805
PMC: 9574594.
DOI: 10.1016/j.antiviral.2022.105445.
Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases.
Lan Q, Wang L, Jiao F, Lu L, Xia S, Jiang S
J Med Virol. 2022; 95(1):e28143.
PMID: 36098460
PMC: 9539121.
DOI: 10.1002/jmv.28143.
Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2.
Pastorio C, Zech F, Noettger S, Jung C, Jacob T, Sanderson T
Cell Host Microbe. 2022; 30(9):1255-1268.e5.
PMID: 35931073
PMC: 9289044.
DOI: 10.1016/j.chom.2022.07.006.
Intrinsic furin-mediated cleavability of the spike S1/S2 site from SARS-CoV-2 variant B.1.1.529 (Omicron).
Lubinski B, Jaimes J, Whittaker G
bioRxiv. 2022; .
PMID: 35923311
PMC: 9347273.
DOI: 10.1101/2022.04.20.488969.
Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.
Zhou H, Mohlenberg M, Thakor J, Tuli H, Wang P, Assaraf Y
Clin Microbiol Rev. 2022; 35(3):e0001422.
PMID: 35862736
PMC: 9491202.
DOI: 10.1128/cmr.00014-22.
Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages.
Xia S, Wang L, Zhu Y, Lu L, Jiang S
Signal Transduct Target Ther. 2022; 7(1):241.
PMID: 35853878
PMC: 9295084.
DOI: 10.1038/s41392-022-01105-9.
SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron.
Zhu Y, Dong X, Liu N, Wu T, Chong H, Lei X
Emerg Microbes Infect. 2022; 11(1):1819-1827.
PMID: 35786417
PMC: 9310806.
DOI: 10.1080/22221751.2022.2098060.
